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The issue of antimicrobial resistance for 
humankind does not need any introduction 
anymore. It is a widely recognised global 
health threat, that has sparked increasing 
attention, as acknowledged at the World 
Health Assembly at its 68th meeting in May 
2015, and at the General Assembly of the 
United Nations (UNGA) in September 
2016.1 2 The World Health Assembly adopted 
a Global Action Plan on Antimicrobial Resis-
tance that was endorsed by the UNGA. The 
plan formulates five key objectives; we draw 
attention to two of these. In its first objective, 
the Global Action Plan calls for improving 
‘awareness and understanding of antimicro-
bial resistance through effective communi-
cation, education and training’. The fourth 
objective aims at ‘optimising the use of anti-
microbial medicines in human and animal 
health’.
In their recent publication, Klein and 
coworkers state, in line with the first objective 
of the plan, that it is important to communi-
cate trends in antibiotic resistance to a broad 
audience, and that this should be done in a 
clear and unambiguous way.3 To this purpose, 
they propose to use a Drug Resistance Index 
(DRI), as a measure of antibiotic effectiveness 
in relation to drug resistance. The DRI was 
described in a previous article by Laxmina-
rayan and Klugman.4 It was developed as an 
easy to use tool to aid politicians and health 
authorities in getting an estimate of a coun-
try’s availability of effective antibiotics to treat 
the most common or severe bacterial infec-
tions in that given country. By combining, 
in a single metric, the use of various antibi-
otic groups and the resistance proportions 
of several pathogens, the aim is to improve 
and simplify communication about the 
effectiveness and consequences of antibiotic 
therapy. A low DRI is meant to indicate a high 
effectiveness of antibiotic therapy and a high 
DRI the opposite.
Unfortunately, a closer look at the DRI 
shows that combining different data in a 
single metric provides unclear and ambig-
uous information. The lack of inherent logic 
of this metric will more likely confuse than 
clarify. The intricacies of the DRI are three-
fold. First, this metric is calculated by dividing 
two proportions: the proportion of use of 
each antibiotic is divided by the proportion 
of resistance to that antibiotic. Second, it 
combines total antibiotic use, which, for the 
large majority, mostly occurs in the commu-
nity, with resistance proportions in pathogens 
that are mostly responsible for infections in 
hospitals and other healthcare settings.
The DRI is thus created with data from 
two different care sectors with different 
Summary box
 ► The Drug Resistance Index (DRI) is proposed as 
measure of antibiotic effectiveness in a given coun-
try, by combining, in a single metric the use of vari-
ous antibiotic groups and the resistance proportions 
of several pathogens.
 ► The DRI is a complicated measure that gives results 
that cannot be understood by common knowledge 
and logic.
 ► The DRI conveys a wrong message. A low DRI is 
meant to represent good antibiotic efficacy, but a low 
DRI may be the result of unnecessary, excessive use 
of too broad-spectrum antibiotics.
 ► Restrictive use of antibiotics is one of the corner-
stones in the fight against antimicrobial resistance, 
therefore the DRI, whose interpretation may promote 
the opposite, should not be used.
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characteristics of patients, pathogens and antibiotic use. 
Such data should not be combined in one single index. 
In addition, for many countries, the reliability of the 
proportions used in the equation is questionable, since 
both antibiotic use, and resistance data often are rather 
raw estimates. In many countries, antibiotic resistance 
proportions are based on an extrapolation from very 
low numbers of clinical isolates, mirroring an often very 
sporadic or selective sampling procedure in hospitals. 
Third, it combines aggregated data of use of all antibi-
otics with aggregated resistance rates of different patho-
gens. Not every antibiotic is useful for every pathogen, 
and some are more important than others. In one 
country, increasing resistance to amoxicillin-clavulanic 
acid may be considered important, while in another of 
no consequence. Combining data in the way proposed 
may appear impressive but will not really add clarity.
A few examples of DRIs from Klein et al illustrate 
these problems.3 The USA has a lower DRI than, for 
example, the Netherlands or Australia. This does not 
reflect the well-known low antibiotic resistance propor-
tions (as reported by the European Antimicrobial Resis-
tance Surveillance Network), the low antibiotic use (as 
reported by the European Surveillance of Antimicrobial 
Consumption Network) and the nation-wide implemen-
tation of effective antibiotic stewardship programmes in 
the Netherlands.5 6 It does also not reflect the low resis-
tance proportions of Gram-negative bacteria in Australia 
(these are even lower than those in the Netherlands), but 
possibly the position of the Australian DRI is influenced 
by high resistance proportions of Staphylococcus aureus 
and Enterococcus spp. in this country, compared with many 
other countries.7 In both examples, the DRI does not 
seem to reflect reality.
The explanation for the respective positions of the 
Netherlands and the USA is quite likely the following: 
while prescribers in the Netherlands may see no reason 
to adapt their antibiotic prescription patterns in the 
community to resistance proportions seen in mainly 
healthcare-associated pathogens, studies have shown that 
clinicians in the USA tend to prescribe broad-spectrum 
antibiotics in the community at such a high rates if they 
adapted community antibiotic prescribing to the resis-
tance proportions in healthcare-associated pathogens 
(although this should not be done).8–10 The respective 
positions of Australia and the USA are difficult to under-
stand, as they do not correspond with the lower resistance 
rates, both in Gram-negative and Gram-positive patho-
gens, in Australia, than in the USA, despite comparable 
antibiotic use rates in these countries.11 We propose that 
Klein et al investigate how developing separate DRIs for 
the community and the hospital sectors would influence 
conclusions.
Furthermore, DRIs might be counterproductive in 
reaching the fourth objective of the Global Action Plan, 
that is, ‘optimising the use of antimicrobial medicines in 
human and animal health’. Even more important than 
its complexity, which makes it difficult to understand why 
a certain country has a certain DRI, we fear that the DRI 
may convey the wrong message. Indeed, a low DRI may 
intuitively be interpreted as a low level of antimicrobial 
resistance, which is not necessarily the case. A country 
with high resistance levels may have a low DRI when it 
uses broad-spectrum antibiotics routinely, as shown above 
by the example of the USA.
To take it even further, a low DRI may be the result of 
resistance levels that are actually low and broad-spectrum 
antibiotics being used without a good reason. In both 
instances, these countries with low DRI will be seen as 
performing well. This may be perceived as encouraging 
by politicians and as reassuring by clinicians, who could 
continue prescribing broad-spectrum antibiotics when 
they are not necessary. This issue is briefly touched on 
by Klein et al: ‘a country with high per capita drug use 
would not have a high DRI, if resistance rates to the most 
frequently used drugs were low’. However, the conse-
quence of condoning broad-spectrum antibiotics is well 
known. It is widely accepted that high and broad-spec-
trum antibiotic use should be curtailed in order to 
decrease selection of antibiotic-resistant and especially 
multidrug-resistant microorganisms. The DRI does not 
provide information on use of broad-spectrum antibi-
otics and in which countries it is common, which might 
give the false impression that an indiscriminate use of 
broad-spectrum antibiotics is a good thing, as it leads to a 
very good, low DRI.
Therefore, we conclude that the DRI in its present 
form is not a useful tool to communicate to a wide audi-
ence. First, because its complexity makes it difficult to 
interpret, and second because the DRI may promote the 
unnecessary use of broad-spectrum antibiotics, poten-
tially reversing many good initiatives undertaken to over-
come and counter the global problem of antimicrobial 
resistance. As restrictive use of antibiotics is one of the 
cornerstones in the fight against antimicrobial resistance, 
we should not use indicators whose interpretation may 
promote the opposite.
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